Business Wire

Edwards Launches New Range of Passive Gauges and Controllers for Specialized High Vacuum Applications

Del

Edwards is introducing a new range of passive gauges and controllers to meet the needs of those customers with specialized applications across the high energy physics and ultra high vacuum sectors. The new range of gauges and controllers are ideal in a wide range of applications, from UHV systems to process industries, or wherever the use of an active gauge is not possible.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170802005047/en/

Edwards Launches New Range of Passive Gauges and Controllers for Specialized High Vacuum Application ...

Edwards Launches New Range of Passive Gauges and Controllers for Specialized High Vacuum Applications (Photo: Business Wire)

The new Edwards range of passive gauges comprises Pirani, Penning and both Bayard-Alpert and Extractor Ion gauge heads. These are used in conjunction with a passive gauge controller to display pressure and offer an interface for the user. Pressure ranges of 10-9 to 1000 mbar are covered by the PGC201 controller together with Pirani and Penning gauge, and for pressure ranges of 10-12 to 1000 mbar are covered by the PGC202 controller together with Pirani and Ion gauge.

“We are pleased to launch this new range of passive gauges and controllers”, commented Dave Goodwin, Senior Product Manager, High Vacuum, Edwards. “They are an excellent addition to the Edwards portfolio of vacuum solutions and enhance our customer product offering.”

Full details can be found at www.edwardsvacuum.com

About Edwards

Edwards is a leading developer and manufacturer of sophisticated vacuum products, exhaust management systems and related value-added services. These are integral to manufacturing processes for semiconductors, flat panel displays, LEDs and solar cells; are used within an increasingly diverse range of industrial processes including power, glass and other coating applications, steel and other metallurgy, pharmaceutical and chemical; and for both scientific instruments and a wide range of R&D applications.

Edwards has over 4,000 employees worldwide engaged in the design, manufacture and support of high technology vacuum and exhaust management equipment. Edwards has state-of-the-art manufacturing facilities in Europe, Asia and North America.

Contact information

Edwards
Rebecca Walder
+44 (0) 1293 603103
PR@edwardsvacuum.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Open Fiber Powers Its Optical Network With SM Optics WDM ROADM22.10.2018 07:00Pressemelding

Open Fiber a national wholesales operator awards SM Optics, part of SIAE MICROELETTRONICA group a contract to supply and deploy WSS-free WDM ROADM technology extending fibre connectivity from their fibre backbone to metro/regional sites. The new network transports the FTTH (fibre-to-the-home) and FWA (Fixed-wireless-access) aggregated traffic, delivering ultra-broadband service to houses and local businesses. Open Fiber mission is to build a nationwide fiber network, bringing fibre connectivity to the vast majority of households and enterprises in the country, with a target of almost 19 million property units. This optical access infrastructure will enable operators delivering next generation services from FTTH broadband network for data, gaming, video streaming and mobile connectivity to 5G and IoT. SM Optics optical transport solution offers unprecedented flexibility in the smallest footprint, successfully meeting the challenge of limited space deployment and low power consumption. F

Zscaler Extends Cloud DLP Service with Inline Exact Data Match for Massive Data Sets Covering Users Globally22.10.2018 06:30Pressemelding

Zenith Live Europe – Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today announced inline Exact Data Match (EDM) with native SSL inspection as part of its advanced Cloud Data Loss Prevention (DLP) service. The inline EDM capability extends the Zscaler™ cloud platform to protect against the loss of sensitive information across all users and branches with more precision while reducing the number of false positives to near zero. This service is provided in the Zscaler cloud, providing the capacity of one billion data points per customer across 100 data centers globally. Traditional DLP appliances that sit in the data center are expensive and resource-intensive, and their protection can be subpar, often failing to alert an organization until after data has been compromised. Zscaler’s inline EDM with native SSL inspection blocks sensitive information before it leaves the network. In the first half of 2018, the Zscaler cloud platform blocked an average of 800,000 SSL-encrypted tr

Vivior Chairman Receives Award for Outstanding Contributions to Refractive Surgery22.10.2018 06:00Pressemelding

Michael Mrochen, PhD, Chairman of the Board of Directors at Vivior, receives the Casebeer Award from the International Society of Refractive Surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181021005012/en/ Michael Mrochen, PhD Chairman of the Board of Directors Vivior AG (Photo: Business Wire) The International Society of Refractive Surgery (ISRS), a partner of the American Academy of Ophthalmology, is the leading worldwide organization for refractive surgeons. Each year, ISRS awards members for their special contributions to the ISRS, as well as their dedication to the field. The Casebeer Award recognizes an individual for his or her outstanding contributions to refractive surgery through nontraditional research and development activities (https://www.isrs.org/about-isrs/awards). Michael Mrochen is internationally known for his pioneering work on corneal laser surgery, corneal cross linking, ocular biometry and corn

Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis22.10.2018 05:00Pressemelding

Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis (UC) who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous (IV) induction therapy. At week 52, a statistically significant proportion of patients receiving vedolizumab SC achieved clinical remission** compared to patients receiving placebo (46.2% vs. 14.3%; p<0.001). A similar rate of clinical remission was observed in the vedolizumab IV reference arm (42.6%). These results were presented at the 2018 United European Gastroenterology (UEG) Week congress in Vienna, Austria. “The VISIBLE 1 results highlight that the investigational subcutaneous formulation of vedolizumab helped patients with moderat

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in